Cathie Wood’s ARK sells Personalised stock, buys Freenome shares
ARK ETFs sold 670,746 shares of Personalised (PSNL) for $10.7M, bought 254,668 shares of Freenome (FRNM) for $3.1M, sold 59,477 shares of CareDx (CDNA) for $4M, and bought 29,416 shares of Scribe Therapeutics (SCTX) for $609K. These trades indicate ARK's strategic portfolio adjustments.
How this was made
The 30-second read
Why it matters
The trades are likely to influence short‑term price dynamics for the four biotech stocks, with sell‑offs creating pressure and purchases offering modest support.
Market read
While the disclosed trades are new, they represent routine portfolio rebalancing and offer limited actionable insight for traders.
What to watch
Potential pipeline milestones or trial results for these biotech firms could offset the impact of ARK's trades.
Background
ARK's daily trade disclosures show a strategic shift away from Personalised and CareDx while adding exposure to Freenome and Scribe Therapeutics.
Ticker impact
ARK sold 670,746 shares of Personalised, Inc., valued at $10.68 M, indicating a divestment.
likely pressure as the market prices in the sizable sell-off
ARK's exit signals reduced confidence; the trade size is material for a micro‑cap.
ARK bought 254,668 shares of Freenome, Inc., worth $3.13 M, adding to its recent accumulation.
likely support as the market views the purchase as a vote of confidence
ARK's purchase may boost sentiment; the amount is notable for the stock.
ARK sold 59,477 shares of CareDx, Inc., valued at $3.97 M, continuing a week‑long divestment.
likely pressure as the market absorbs the ongoing reduction
Repeated sales suggest weakening confidence in CDNA.
ARK bought 29,416 shares of Scribe Therapeutics, Inc., worth $0.61 M, adding to a growing stake.
possible slight support as the market notes the new interest
The trade size is small relative to market cap, so impact is limited.
Market effects
Minimal; the trades reflect ARK's rebalancing within the biotech sector.
None; all companies are US‑listed and the effect is limited to individual stocks.
Low; no broader market move is driven by these transactions.
Counterpoint
ARK's exit from PSNL and CDNA may be premature if upcoming data revives interest.
Key entities
- PersonCathie Wood
Founder of ARK Invest, whose fund actions drive market attention.
- FundARK Invest
Active manager whose daily trade disclosures affect listed equities.
